Severe hypothyroidism can present with predominant psychiatric and cognitive symptoms, making diagnosis challenging when classic somatic signs are absent. This poster explores the neurops...
A 65-year-old male veteran with no prior psychiatric history and a past medical history of seizure disorder developed severe, treatment-resistant depression after witnessing his mother’s ...
This project explores the integration of mindfulness meditation with esketamine in the treatment of major depressive disorder. Conducted as a quasi-experimental pilot, the study involved ...
Up to 50% of adults with schizophrenia switch antipsychotic medication within 2 years of treatment initiation. We conducted a real-world analysis of strategies used by healthcare provider...
This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with bipolar I disorder. OLZ/SAM was associated with significantly better ...
Short description: Prior pharmacokinetic studies of X/T in healthy volunteers showed dosing with food reduced trospium bioavailability, potentially impacting tolerability. This open-label...
TV-44749 is a once-monthly subcutaneous long-acting injectable olanzapine, designed to provide sustained efficacy without the risk of post-injection delirium/sedation syndrome (PDSS). Her...
CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with curre...
Jazz DUET (NCT05875974) was a patient-centric, prospective, single-arm, open-label study evaluating effectiveness of low-sodium oxybate (LXB) in IH or narcolepsy. In participants with IH,...
The SAVITRI study evaluated osavampator, a selective positive allosteric modulator of the AMPA receptor (AMPA-PAM), in adults with MDD. Compared with placebo, once-daily oral administrati...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
